Piramal Discovery Solutions offers a comprehensive range of Contract Research Services from our state-of-the-art research centre in India to support drug discovery activities
Piramal offers clinical development services from Phase I to Phase III for various dosage form such as Oral solids, liquids, creams, ointments, and sterile injectable
Piramal offers contract manufacturing for API, HPAPI and a wide variety of dosage forms. Our global manufacturing sites located across North America, Europe and India offer the highest standards of quality and service to the customers
Piramal is the global leader in delivering customer-centric solutions in the field of Antibody Drug Conjugates (ADCs) and other bioconjugates to global biopharmaceutical companies
Piramal’s Generic API division offers an indigenous basket of off-patent APIs for global markets. With the declining pipeline of new drugs in the pharmaceutical industry, our customers are looking for off-patent APIs with competitive cost and quality
Piramal Nutrition Solutions (PNS), division of Piramal Enterprises Limited (PEL) is one of the leading manufacturers of Straight Vitamins and Mineral premixes
With individualized programs in the offering, we offer a fast-track early-stage development service for your ADC and bioconjugate program to meet your needs.
Thank You For Your Interest. Please Enter Your Details
Tailored to meet your needs
Cost-effective proof-of-concept conjugation service to demonstrate the viability of cytotoxic drugs or
monoclonal antibodies for use as therapeutic ADCs.
Customer antibodies for conjugation suitability
Comparison of different chemistries (cysteine and lysine)
Range of different linkers available (cleavable, non-cleavable, and PEGylated)
Variety of payloads available (microtubule disrupting drugs, DNA damaging compounds,
protein ribosome-inactivating toxins, and chelators for radioimmunotherapy)
Preparation of different drug loadings
Analytical characterization and screening of conjugates
Customer cytotoxic or linker technologies
Ability to make various conjugates with model antibodies using linker or drug platforms
Experienced with a range of novel linker technologies
ADC Standards to Benchmark Client Materials
A model antibody with DAR 2 and DAR 4 with different ADC toxins